(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Instructions to Keep up with Your Traded Teeth for Life span - 26 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- 35 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- 4Surging measles cases are 'fire alarm' warning that other diseases could be next
- 510 Work Valuable chances to Assist with supporting Your Advanced degree
- A Couple of Reasonable Guitars for 2024
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- UN mission says no evidence Hezbollah rearming in southern Lebanon
- Revvity says it will exceed 2025 profit forecast range
- Internet Bookkeeping Programming for Consultants
- Improving as a Cook: Culinary Experiences in the Kitchen
- Don’t let food poisoning crash your Thanksgiving dinner
- 6 Methods for further developing Rest Quality
